Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled parallel-group study of erenumab in pediatric episodic migraine
2017-002397-39Phase 3Unknown
- Sponsor
- Amgen
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in episodic migraine and migraine comparing erenumab with placebo (2 arms). Status: unknown.
02
Drugs
erenumab
03
Conditions
episodic migrainemigraine
Beyond the preview
Go deeper on 2017-002397-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002397-39.